Company registration number: 09848787
COMPANY INFORMATION
CONTENTS
STATEMENT OF FINANCIAL POSITION
AS AT 31 MARCH 2026
Page 1
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 MARCH 2026
The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.
The financial statements were approved and authorised for issue by the board and were signed on its behalf by:
The notes on pages 4 to 10 form part of these financial statements.
Page 2
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 MARCH 2026
Page 3
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
Digital Odour Technologies Limited (previously known as Arctech Innovation Limited) is a private company, limited by shares, registered in England and Wales. The company's registered number, registered office and trading address can be found on the Company Information page.
During the year the company changed its name from Arctech Innovation Limited to Digital Odour Technologies Limited.
During the year the company changed its name from Arctech Innovation Limited to Digital Odour Technologies Limited.
2.Accounting policies
The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The following principal accounting policies have been applied:
In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured.
The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which is ten years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives, which is ten years.
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
Page 4
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
2.Accounting policies (continued)
Grants of a revenue nature are recognised in the Statement of comprehensive income in the same period as the related expenditure.
Page 5
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
2.Accounting policies (continued)
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
Development costs are being amortised evenly over their estimated useful life of ten years.
Intangible assets are initially measured at costs. Product development expenditure is capitalised as an intangible asset only if all of certain conditions are met. The capitalisation criteria are as follows:
1. An asset is created that can be separately identified, and which the company intends to use or sell
2. It is technically feasible to complete the development of the asset for use or sale
3. It is probable that the asset will generate future economic benefit
4. The development cost of the asset can be measured reliably
The expected useful lives of intangible assets are reviewed annually. The company does not have any intangible assets with indefinite lives.
Following initial recognition, intangible assets with finite useful lives are carried at cost less accumulated amortisation and accumulated impairment losses. They are amortised on a straight line basis over their estimated useful lives of 10 years.
Research costs are expensed as incurred. Development expenditure incurred on an individual project is capitalised only if specific criteria are met.
Development costs are being amortised evenly over their estimated useful life of ten years.
Intangible assets are initially measured at costs. Product development expenditure is capitalised as an intangible asset only if all of certain conditions are met. The capitalisation criteria are as follows:
1. An asset is created that can be separately identified, and which the company intends to use or sell
2. It is technically feasible to complete the development of the asset for use or sale
3. It is probable that the asset will generate future economic benefit
4. The development cost of the asset can be measured reliably
The expected useful lives of intangible assets are reviewed annually. The company does not have any intangible assets with indefinite lives.
Following initial recognition, intangible assets with finite useful lives are carried at cost less accumulated amortisation and accumulated impairment losses. They are amortised on a straight line basis over their estimated useful lives of 10 years.
Research costs are expensed as incurred. Development expenditure incurred on an individual project is capitalised only if specific criteria are met.
Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.
Depreciation is provided on the following basis:
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.
Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
Page 6
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
2.Accounting policies (continued)
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
Page 7
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
||||||
|
|
Page 8
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
During the year the Company adopted new Articles of Association and allotted 4,191,722 A Ordinary shares of £0.000001 each. The allotment raised cash consideration of £3,732,086 and increased the nominal value of share capital by £4.191722, with the balance credited to share premium.
Following the allotment, the Company's issued share capital comprised:
11,076,969 Ordinary shares; and
4,191,722 A Ordinary shares.
Total shares in issue at 31 March 2026 were 15,268,691.
The A Ordinary shares are non-redeemable and carry preferential rights on a return of capital.
Following the allotment, the Company's issued share capital comprised:
11,076,969 Ordinary shares; and
4,191,722 A Ordinary shares.
Total shares in issue at 31 March 2026 were 15,268,691.
The A Ordinary shares are non-redeemable and carry preferential rights on a return of capital.
Page 9
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026
Page 10